

Drug Susceptibility Test Results for M. tuberculosis Complex Isolates from the CDC Model Performance Evaluation Program

Form Approved

OMB No. 0920-0600

Expiration Date: XX/XX/20XX

CDC estimates the average public reporting burden for this collection of information as 15 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS H21-8, Atlanta, Georgia 30333; ATTN: PRA (0920-0600).

Instructions

-
For each survey submitted, two growth-based drug susceptibility test methods and three molecular test method can be entered.

-
Sensititre, if performed, must be entered as the first method.

-
All results for the MPEP survey must be entered at one time.

-
For questions or comments, contact TBMPEP@cdc.gov.

*Enter MPEP number _____
*Name of person completing form _____
*Title _____
*Email _____
*must provide value

Enter MPEP number

Please indicate the primary classification of your laboratory

- ☐ Hospital
☐ Public Health (e.g., local, county, state, territorial)
☐ Independent/Reference (non-hospital based)
☐ Federal
☐ Other
-

Please describe your laboratory classification

On what date were the MPEP cultures received in your laboratory?

Upon arrival, what was the condition of the cultures in the panel?

- ☐ Satisfactory
☐ Unsatisfactory
-

Please describe the unsatisfactory condition of the cultures when they arrived

In the last calendar year (January 1 - December 31, 2024), how many isolates of *M. tuberculosis* complex (MTBC) did your laboratory test for drug susceptibilities? (Please exclude quality control isolates)

Did your laboratory perform MTBC growth-based drug susceptibility testing (DST) for the panel in this shipment?

- ☐ Yes
☐ No
-

What method was performed in your laboratory for MTBC growth-based drug susceptibility testing (DST) for testing the panel in this shipment?
(Only one method can be selected. If multiple methods were performed, there will be an opportunity to enter those results after the first method.)

- ☐ Agar Proportion (Middlebrook 7H10 or 7H11)
☐ MGIT System
☐ MIC Testing
☐ VersaTrek Myco

Isolate 2025A**Please enter your growth-based DST results**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Bedaquiline	☐	☐	☐	☐	☐	☐
Linezolid	☐	☐	☐	☐	☐	☐
Clofazimine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Isolate 2025B**Please enter growth-based drug susceptibility results**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Bedaquiline	☐	☐	☐	☐	☐	☐
Linezolid	☐	☐	☐	☐	☐	☐
Clofazimine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Isolate 2025C**Please enter growth-based drug susceptibility results**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Bedaquiline	☐	☐	☐	☐	☐	☐
Linezolid	☐	☐	☐	☐	☐	☐
Clofazimine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Isolate 2025D**Please enter growth-based drug susceptibility results**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Bedaquiline	☐	☐	☐	☐	☐	☐
Linezolid	☐	☐	☐	☐	☐	☐
Clofazamine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Isolate 2025E**Please enter growth-based drug susceptibility results**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

Did your laboratory perform growth-based DST on additional drugs by the initial method selected?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Bedaquiline	☐	☐	☐	☐	☐	☐
Linezolid	☐	☐	☐	☐	☐	☐
Clofazimine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Please provide the specific MIC testing method performed

Isolate 2025A MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)

Rifampin _____
Isoniazid low _____
Isoniazid high _____
Ethambutol _____

Streptomycin

Ofloxacin

Ciprofloxacin

Moxifloxacin

Levofloxacin

Amikacin

Kanamycin

Capreomycin

Ethionamide

Rifabutin

Cycloserine

Para-aminosalicylic Acid

Rifapentine

Bedaquiline

Linezolid

Clofazimine

Delamanid

Pretomanid

Additional MIC Comments

Isolate 2025B MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)

Rifampin _____
Isoniazid low _____
Isoniazid high _____
Ethambutol _____
Streptomycin _____
Ofloxacin _____
Ciprofloxacin _____
Moxifloxacin _____
Levofloxacin _____
Amikacin _____
Kanamycin _____
Capreomycin _____
Ethionamide _____
Rifabutin _____
Cycloserine _____
Para-aminosalicylic Acid _____
Rifapentine _____
Bedaquiline _____
Linezolid _____
Clofazimine _____
Delamanid _____
Pretomanid _____

Additional MIC Comments

Isolate 2025C MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)

Rifampin _____
Isoniazid low _____
Isoniazid high _____
Ethambutol _____
Streptomycin _____
Ofloxacin _____
Ciprofloxacin _____
Moxifloxacin _____
Levofloxacin _____
Amikacin _____
Kanamycin _____
Capreomycin _____
Ethionamide _____
Rifabutin _____
Cycloserine _____
Para-aminosalicylic Acid _____
Rifapentine _____
Bedaquiline _____
Linezolid _____
Clofazimine _____
Delamanid _____
Pretomanid _____

Additional MIC Comments

Isolate 2025D MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)

Rifampin _____
Isoniazid low _____
Isoniazid high _____
Ethambutol _____
Streptomycin _____
Ofloxacin _____
Ciprofloxacin _____
Moxifloxacin _____
Levofloxacin _____
Amikacin _____
Kanamycin _____
Capreomycin _____
Ethionamide _____
Rifabutin _____
Cycloserine _____
Para-aminosalicylic Acid _____
Rifapentine _____
Bedaquiline _____
Linezolid _____
Clofazimine _____
Delamanid _____
Pretomanid _____

Additional MIC Comments

Isolate 2025E MIC Testing Results

Enter MIC drug susceptibility interpretation Enter quantitative MIC results (ug/ml)

Rifampin _____
Isoniazid low _____
Isoniazid high _____
Ethambutol _____
Streptomycin _____
Ofloxacin _____
Ciprofloxacin _____
Moxifloxacin _____
Levofloxacin _____
Amikacin _____
Kanamycin _____
Capreomycin _____
Ethionamide _____
Rifabutin _____
Cycloserine _____
Para-aminosalicylic Acid _____
Rifapentine _____
Bedaquiline _____
Linezolid _____
Clofazimine _____
Delamanid _____
Pretomanid _____

Additional MIC Comments

Did your laboratory perform a second growth-based DST method?

- ☐ Yes
☐ No

Select the second growth-based DST method:

- ☐ Agar Proportion
☐ MGIT System
☐ VersaTrek Myco

Isolate 2025A--Test Method 2**For your second growth-based method, enter drug susceptibility results.**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

For this second test method, did your laboratory
perform DST on additional drugs?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Bedaquiline	☐	☐	☐	☐	☐	☐
Linezolid	☐	☐	☐	☐	☐	☐
Clofazimine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Isolate 2025B--Test Method 2**For your second growth-based method, enter drug susceptibility results.**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

For this second test method, did your laboratory
perform DST on additional drugs?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Bedaquiline	☐	☐	☐	☐	☐	☐
Linezolid	☐	☐	☐	☐	☐	☐
Clofazimine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Isolate 2025C--Test Method 2**For your second growth-based method, enter drug susceptibility results.**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

For this second test method, did your laboratory perform DST on additional drugs?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Bedaquiline	☐	☐	☐	☐	☐	☐
Linezolid	☐	☐	☐	☐	☐	☐
Clofazimine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Isolate 2025D--Test Method 2**For your second growth-based method, enter drug susceptibility results.**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

For this second test method, did your laboratory
perform DST on additional drugs?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-Aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Clofazamine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Isolate 2025E--Test Method 2**For your second growth-based method, enter drug susceptibility results.**

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Rifampin	☐	☐	☐	☐	☐	☐
Isoniazid low	☐	☐	☐	☐	☐	☐
Isoniazid high	☐	☐	☐	☐	☐	☐
Ethambutol	☐	☐	☐	☐	☐	☐
Pyrazinamide	☐	☐	☐	☐	☐	☐
Streptomycin	☐	☐	☐	☐	☐	☐

For this second test method, did your laboratory perform DST on additional drugs?

☐ Yes
☐ No

	Susceptible	Resistant	Intermediate	Contaminated / No Growth	No Interpretation	Not Done
Ofloxacin	☐	☐	☐	☐	☐	☐
Ciprofloxacin	☐	☐	☐	☐	☐	☐
Moxifloxacin	☐	☐	☐	☐	☐	☐
Levofloxacin	☐	☐	☐	☐	☐	☐
Amikacin	☐	☐	☐	☐	☐	☐
Kanamycin	☐	☐	☐	☐	☐	☐
Capreomycin	☐	☐	☐	☐	☐	☐
Ethionamide	☐	☐	☐	☐	☐	☐
Rifabutin	☐	☐	☐	☐	☐	☐
Cycloserine	☐	☐	☐	☐	☐	☐
Para-Aminosalicylic Acid	☐	☐	☐	☐	☐	☐
Rifapentine	☐	☐	☐	☐	☐	☐
Bedaquiline	☐	☐	☐	☐	☐	☐
Linezolid	☐	☐	☐	☐	☐	☐
Clofazimine	☐	☐	☐	☐	☐	☐
Delamanid	☐	☐	☐	☐	☐	☐
Pretomanid	☐	☐	☐	☐	☐	☐

Comments

Did your laboratory perform detection of drug resistance using a molecular method?

☐ Yes
☐ No

Please select the molecular method performed

- ☐ Xpert MTB/RIF (Cepheid)
☐ Genotype MTDRplus/MTDRsl (Hain Lifescience)
☐ Conventional Targeted DNA Sequencing (e.g., pyrosequencing, Sanger)
☐ Next Generation Targeted DNA Sequencing (e.g., Illumina amplicon sequencing, Deeplex Myc-TB, Nanopore)
☐ Whole Genome Sequencing
☐ Other method

Please provide the specific Next Generation Targeted DNA sequencing method performed

Please provide the specific Whole Genome Sequencing method performed

Please provide the Other molecular method performed

Isolate 2025A Molecular Results Please enter your reportable molecular results.

Enter molecular results Enter specific mutation(s) detected

Rifamycins (Rifampin, Rifabutin, Rifapentine) _____

Isoniazid _____

Ethambutol _____

Pyrazinamide _____

Streptomycin _____

Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

Amikacin _____

Kanamycin _____

Capreomycin _____

Ethionamide _____

Cycloserine _____

Para-aminosalicylic Acid _____

Bedaquiline _____

Linezolid _____

Clofazimine _____

Delamanid _____

Pretomanid _____

Additional Molecular Comments

Isolate 2025B Molecular Results Please enter your reportable molecular results.

Enter molecular results Enter specific mutation(s) detected

Rifamycins (Rifampin, Rifabutin, Rifapentine) _____

Isoniazid _____

Ethambutol _____

Pyrazinamide _____

Streptomycin _____

Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

Amikacin _____

Kanamycin _____

Capreomycin _____

Ethionamide _____

Cycloserine _____

Para-aminosalicylic Acid _____

Bedaquiline _____

Linezolid _____

Clofazimine _____

Delamanid _____
Pretomanid _____

Additional Molecular Comments

Isolate 2025C Molecular Results Please enter your reportable molecular results.

Enter molecular results Enter specific mutation(s) detected

Rifamycins (Rifampin, Rifabutin, Rifapentine) _____

Isoniazid _____

Ethambutol _____

Pyrazinamide _____

Streptomycin _____

Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

Amikacin _____

Kanamycin _____

Capreomycin _____

Ethionamide _____

Cycloserine _____

Para-aminosalicylic Acid _____

Bedaquiline _____

Linezolid _____

Clofazimine _____

Delamanid _____

Pretomanid _____

Additional Molecular Comments

Isolate 2025D Molecular Results Please enter your reportable molecular results.

Enter molecular results Enter specific mutation(s) detected

Rifamycins (Rifampin, Rifabutin, Rifapentine) _____

Isoniazid _____

Ethambutol _____

Pyrazinamide _____

Streptomycin _____

Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

Amikacin _____

Kanamycin _____

Capreomycin _____

Ethionamide _____

Cycloserine _____

Para-aminosalicylic Acid _____

Bedaquiline _____

Linezolid _____

Clofazimine _____

Delamanid _____

Pretomanid _____

Additional Molecular Comments

Isolate 2025E Molecular Results Please enter your reportable molecular results.

Enter molecular results Enter specific mutation(s) detected
 Rifamycins (Rifampin, Rifabutin, Rifapentine) _____
 Isoniazid _____
 Ethambutol _____
 Pyrazinamide _____
 Streptomycin _____
 Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____
 Amikacin _____
 Kanamycin _____
 Capreomycin _____
 Ethionamide _____
 Cycloserine _____
 Para-aminosalicylic Acid _____
 Bedaquiline _____
 Linezolid _____
 Clofazimine _____
 Delamanid _____
 Pretomanid _____

Additional Molecular Comments

Did your laboratory perform a second molecular method for detection of drug resistance?

- ☐ Yes
☐ No

Please select the molecular method performed

- ☐ Xpert MTB/RIF (Cepheid)
☐ Genotype MTDRplus/MTDRsl (Hain Lifescience)
☐ Conventional Targeted DNA Sequencing (e.g., pyrosequencing, Sanger)
☐ Next Generation Targeted DNA Sequencing (e.g., Illumina amplicon sequencing, Deeplex Myc-TB, Nanopore)
☐ Whole Genome Sequencing
☐ Other method

Please provide the specific Next Generation Targeted DNA sequencing method performed

Please provide the specific Whole Genome Sequencing method performed

Please provide the Other molecular method performed

Isolate 2025A Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
 Rifamycins (Rifampin, Rifabutin, Rifapentine) _____
 Isoniazid _____
 Ethambutol _____
 Pyrazinamide _____
 Streptomycin _____
 Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____

 Amikacin _____
 Kanamycin _____
 Capreomycin _____
 Ethionamide _____
 Cycloserine _____
 Para-aminosalicylic Acid _____
 Bedaquiline _____
 Linezolid _____

Clofazimine _____
Delamanid _____
Pretomanid _____

Additional Molecular Comments

Isolate 2025B Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____
Isoniazid _____
Ethambutol _____
Pyrazinamide _____
Streptomycin _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

Amikacin _____
Kanamycin _____
Capreomycin _____
Ethionamide _____
Cycloserine _____
Para-aminosalicylic Acid _____
Bedaquiline _____
Linezolid _____
Clofazimine _____
Delamanid _____
Pretomanid _____

Additional Molecular Comments

Isolate 2025C Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____
Isoniazid _____
Ethambutol _____
Pyrazinamide _____
Streptomycin _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

Amikacin _____
Kanamycin _____
Capreomycin _____
Ethionamide _____
Cycloserine _____
Para-aminosalicylic Acid _____
Bedaquiline _____
Linezolid _____
Clofazimine _____
Delamanid _____
Pretomanid _____

Additional Molecular Comments

Isolate 2025D Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected

Rifamycins (Rifampin, Rifabutin, Rifapentine) _____

Isoniazid _____

Ethambutol _____

Pyrazinamide _____

Streptomycin _____

Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin)

Amikacin _____

Kanamycin _____

Capreomycin _____

Ethionamide _____

Cycloserine _____

Para-aminosalicylic Acid _____

Bedaquiline _____

Linezolid _____

Clofazimine _____

Delamanid _____

Pretomanid _____

Additional Molecular Comments

Isolate 2025E Molecular Results--Test Method 2 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected

Rifamycins (Rifampin, Rifabutin, Rifapentine) _____

Isoniazid _____

Ethambutol _____

Pyrazinamide _____

Streptomycin _____

Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____

Amikacin _____

Kanamycin _____

Capreomycin _____

Ethionamide _____

Cycloserine _____

Para-aminosalicylic Acid _____

Bedaquiline _____

Linezolid _____

Clofazimine _____

Delamanid _____

Pretomanid _____

Additional Molecular Comments

Did your laboratory perform a third molecular method
for detection of drug resistance?☐ Yes☐ No

Please select the molecular method performed

- ☐ Xpert MTB/RIF (Cepheid)
☐ Genotype MTDRplus/MTDRsl (Hain Lifescience)
☐ Conventional Targeted DNA Sequencing (e.g., pyrosequencing, Sanger)
☐ Next Generation Targeted DNA Sequencing (e.g., Illumina amplicon sequencing, Deeplex Myc-TB, Nanopore)
☐ Whole Genome Sequencing
☐ Other method

Please provide the specific Next Generation Targeted DNA sequencing method performed

Please provide the specific Whole Genome Sequencing method performed

Please provide the Other molecular method performed

Isolate 2025A Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected

Rifamycins (Rifampin, Rifabutin, Rifapentine) _____

Isoniazid _____

Ethambutol _____

Pyrazinamide _____

Streptomycin _____

Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____

Amikacin _____

Kanamycin _____

Capreomycin _____

Ethionamide _____

Cycloserine _____

Para-aminosalicylic Acid _____

Bedaquiline _____

Linezolid _____

Clofazimine _____

Delamanid _____

Pretomanid _____

Additional Molecular Comments

Isolate 2025B Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected

Rifamycins (Rifampin, Rifabutin, Rifapentine) _____

Isoniazid _____

Ethambutol _____

Pyrazinamide _____

Streptomycin _____

Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____

Amikacin _____

Kanamycin _____

Capreomycin _____

Ethionamide _____

Cycloserine _____

Para-aminosalicylic Acid _____

Bedaquiline _____

Linezolid _____

Clofazimine _____

Delamanid _____

Pretomanid _____

Additional Molecular Comments

Isolate 2025C Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____
Isoniazid _____
Ethambutol _____
Pyrazinamide _____
Streptomycin _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____
Amikacin _____
Kanamycin _____
Capreomycin _____
Ethionamide _____
Cycloserine _____
Para-aminosalicylic Acid _____
Bedaquiline _____
Linezolid _____
Clofazimine _____
Delamanid _____
Pretomanid _____

Additional Molecular Comments

Isolate 2025D Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____
Isoniazid _____
Ethambutol _____
Pyrazinamide _____
Streptomycin _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____
Amikacin _____
Kanamycin _____
Capreomycin _____
Ethionamide _____
Cycloserine _____
Para-aminosalicylic Acid _____
Bedaquiline _____
Linezolid _____
Clofazimine _____
Delamanid _____
Pretomanid _____

Additional Molecular Comments

Isolate 2025E Molecular Results--Test Method 3 Please enter your reportable molecular DST results.

Enter molecular results Enter specific mutation(s) detected
Rifamycins (Rifampin, Rifabutin, Rifapentine) _____
Isoniazid _____
Ethambutol _____
Pyrazinamide _____
Streptomycin _____
Fluoroquinolones (Moxifloxacin, Levofloxacin, Ofloxacin) _____
Amikacin _____
Kanamycin _____
Capreomycin _____

Ethionamide _____
Cycloserine _____
Para-aminosalicylic Acid _____
Bedaquiline _____
Linezolid _____
Clofazimine _____
Delamanid _____
Pretomanid _____

Additional Molecular Comments

Thank you for completing the survey.

Upon submission, you will have the opportunity to save a copy of your submitted responses.

Please either download a PDF copy or send a PDF copy by email on the next screen.